Bristol-Myers Squibb and Pfizer have presented the results of the Phase III trial to compare apixaban (Eliquis) to enoxaparin in acutely ill medical patients.

In the study, patients randomised to apixaban received daily injections of enoxaparin placebo for a minimum of 6 days and patients randomised to enoxaparin received apixaban placebo tablets for 30 days.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It was found that the apixaban arm had a 13% lower rate of events than enoxaparin followed by placebo.

The primary efficacy endpoint occurred in 2.71% of patients in the apixaban group compared to 3.06% in the enoxaparin group.

Apixaban is currently being evaluated in ongoing trials for the treatment of recurrent venous thromboembolism, in the Phase III Amplify and Amplify-Ext trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact